Antriabio in Louisville changes name to Rezolute Inc.

.LOUISVILLE — Antriabio (OTC: ANTB), a clinical-stage biopharmaceutical company, has changed its name to Rezolute Inc.

The company specializes in developing drug therapies for metabolic and orphan diseases, that is, diseases that are rare or prevalent in developing countries and have few pharmaceutical treatments.

Rezolute has entered into a license agreement with Xoma Corp. (Nasdaq: XOMA), that provides Rezolute exclusive global rights to develop and commercialize RZ358, formerly called XOMA 358, to treat Congenital Hyperinsulinism.

Xoma is a company that develops therapeutic antibodies.

RZ358 is an antibody that counteracts…